Correspondence | Published:

Medicare formulary coverage for top-selling biologics

Nature Biotechnology volume 27, pages 10821084 (2009) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Biotechnol. Healthcare. 3, 28–35 (2006).

  2. 2.

    , , , & Health Aff. (Millwood) 25, 1332–1339 (2006).

  3. 3.

    Health Aff. (Millwood) 25, 1205–1217 (2006).

  4. 4.

    , , , & Am. Med. Assoc. 297, 2596–2602 (2007).

  5. 5.

    , , & Health Aff. (Millwood) 25, 1240–1248 (2006).

  6. 6.

    IMS: Global biotech sales up 12.5% in 2007. (2008) .

  7. 7.

    & Manag. Care Pharm. 12, 736–744 (2006).

  8. 8.

    , & Coverage and Pricing of Drugs That Can Be Covered Under Part B and Part D (MedPAC, Washington, DC, 2007).

  9. 9.

    , , , & Psychiatr. Serv. 58, 308–310 (2007).

  10. 10.

    , & Drugs on Specialty Tiers in Part D (MedPAC, Washington, DC, 2009).

  11. 11.

    , , & Medicare Part D Data Spotlight: Specialty Tiers (Kaiser Family Foundation, Menlo Park, California, USA, 2009).

  12. 12.

    The Tier 4 Phenomenon: Shifting the High Cost of Drugs to Consumers (AARP, Washington, DC, 2009)

Download references

Acknowledgements

The authors are grateful for contributions to this paper from C. Hosenfeld. This study was funded by two grants to K.A.P. from the US National Cancer Institute (R01CA101849 and P01CA130818) and a grant from the Aetna Foundation (unrestricted).

Author information

Affiliations

  1. Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, California, USA.

    • Su-Ying Liang
    •  & Kathryn A Phillips
  2. Division of General Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

    • Jennifer S Haas

Authors

  1. Search for Su-Ying Liang in:

  2. Search for Jennifer S Haas in:

  3. Search for Kathryn A Phillips in:

Competing interests

S.-Y.L., J.S.H. and K.A.P. received funding from a research grant from the Aetna Foundation to study the utilization of emerging genomic technologies. J.S.H. received salary support from a research grant from Pfizer to study reporting of adverse drug events to the FDA.

Corresponding author

Correspondence to Su-Ying Liang.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt1209-1082

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing